Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Deruxtecan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Datopotamab Shows Clinical Activity in EGFR-Mutated Lung Cancer
    Datopotamab Shows Clinical Activity in EGFR-Mutated Lung Cancer

    05 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241205215995/en

    BUSINESSWIRE
    05 Dec 2024
    Share Share
    Merck, Daiichi's ADC Lung Cancer Trial Shows Promise Despite Deaths
    Merck, Daiichi's ADC Lung Cancer Trial Shows Promise Despite Deaths

    18 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240917471670/en/Patritumab-Deruxtecan-Demonstrated-Statistically-Significant-Improvement-in-Progression-Free-Survival-Versus-Doublet-Chemotherapy-in-Patients-with-Locally-Advanced-or-Metastatic-EGFR-Mutated-Non-Small-Cell-Lung-Cancer-in-HERTHENA-Lung02-Phase-3-Trial

    BUSINESSWIRE
    18 Sep 2024
    Share Share
    ENHERTU Shows Activity In HER2+ Breast Cancer With Brain Metastases
    ENHERTU Shows Activity In HER2+ Breast Cancer With Brain Metastases

    13 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240912472756/en

    BUSINESSWIRE
    13 Sep 2024
    Share Share
    Ifinatamab Deruxtecan Shows Promise In Small Cell Lung Cancer Trial
    Ifinatamab Deruxtecan Shows Promise In Small Cell Lung Cancer Trial

    07 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240906264620/en

    BUSINESSWIRE
    07 Sep 2024
    Share Share
    First Patient Dosed In IDeate-Lung02 Trial Of Ifinatamab Deruxtecan
    First Patient Dosed In IDeate-Lung02 Trial Of Ifinatamab Deruxtecan

    03 Aug 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=171660&sid=2

    PHARMABIZ
    03 Aug 2024
    Share Share
    IDeate-Lung02 Phase 3 Trial Of Ifinatamab Deruxtecan Initiated
    IDeate-Lung02 Phase 3 Trial Of Ifinatamab Deruxtecan Initiated

    01 Aug 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240731774917/en/IDeate-Lung02-Phase-3-Trial-of-Ifinatamab-Deruxtecan-Initiated-in-Patients-with-Relapsed-Small-Cell-Lung-Cancer

    BUSINESSWIRE
    01 Aug 2024
    Share Share